GPDA 、CA72-4 、CA50 联检在胃癌诊断中的价值

 目的 探讨GPDA、CA72-4、CA50三项联检对胃癌的临床诊断价值。方法 采用电化学发光免疫分析、放射免疫法及全自动生化分析仪等技术，对125例胃癌、77例胃良性疾病、50例正常健康人血清进行GPDA、CA72-4、CAS0三项检测。结果 胃癌组GPDA、CA72-4、CA50敏感性分别为62．4％、68．0％，54．4％；特异性分别为97．6％、97．6％、98．4％。三项联检敏感性提高到89．6％，与单检比较有统计学意义（P〈0．05）；同时特异性并未明显降低，仍有93．7％。结论 GPDA、CA72-4、CA50可作为临床诊断胃癌的肿瘤标志物，三项联检可明显提高阳性检出率。

The Value of Combined Detection of GPDA, CA72-4 and CA50 in Diagnosis of Gastric Cancer

Objective To study the diagnostic value of Glycyl Proline Dipeptidyl Aminopeptidase (GPDA), CA72-4 and CA50 in gastric cancer. Methods Serum levels of GPDA, CA72-4 and CA50 in 125 patients with gastric cancer, 77 patients with benign gastric tumor and 50 normal controls were measured by electro-chemiluminescence immuno-assay (ECLIA) and radioimmunoassay and automatic biochemical analyzer.Results Sensitivities of GPDA, CA72-4 and CA50 in gastric cancer group were 62.4%, 68.0% and 54.4%, respectively, and the specificities were 97.6%, 97.6% and 98.4%, respectively. The sensitivity of combined detection of three tumor markers increased to 89.6%, and the specificity was 93.7%. Conclusion GPDA, CA72-4 and CA50 can serve as the serum tumor marker in clinical diagnosis of gastric cancer. Combined detection of three kinds of serum tumor makers increases the detective positive rate.